Brind.

Arrowhead Pharmaceuticals and Sarepta entered into a collaboration regarding siRNA programs, including licensing agreement payments starting on August 19, 2025.

4 reports, 3 independent Updated Aug 19
Gone quiet Reached 3 outlets in its first 24 hours
Reports
4
Developments
2
Repetition
75%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Well supportedReported by 3 independent outlets

Arrowhead Pharmaceuticals and Sarepta entered into a collaboration regarding siRNA programs, including licensing agreement payments starting on August 19, 2025.

Who's involved

What this event is mainly about
Arrowhead PharmaceuticalsSarepta

How it developed

Newest first. Tap a step to see who reported it.
  1. Arrowhead and Sarepta reached clinical and licensing milestones in their collaboration regarding siRNA programs.Sub-event
  2. Collaboration established between Arrowhead Pharmaceuticals and Sarepta regarding siRNA programs.1 source

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • Insider MonkeyArrowhead (ARWR) Climbs 24.9% on $100-Million Licensing Revenue We recently published 10 Double-Digit Winners You Wish You Bought Yesterday. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is one of th
  • ZacksSarepta Sells Arrowhead Stake to Fund Milestone Payment Sarepta Therapeutics SRPT announced that it has sold at least $174 million worth of its equity investment in Arrowhead Pharmaceuticals ARWR to
  • Business WireSarepta Therapeutics Announces Advancement of siRNA Collaboration and Sale of Arrowhead Equity Investment - Safety review leading to dose escalation and achievement of first predetermined enrollment
  • Insider MonkeyArrowhead Pharmaceuticals, Inc. (ARWR) Secures $100M Milestone from Sarepta in RNAi Breakthrough Deal We recently compiled a list of 11 Best Future Stocks to Buy Now. Arrowhead Pharmaceuticals, Inc.